Determination of ligand binding capacity of soluble FcγRII and FcγRIII in sera of patients with SLE

Csípő, István; Baráth, Sándor; Kiss, Emese; Szűcs, Gabriella; Szegedi, Gyula; Kávai, M

doi:10.1080/08916930601119344

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking together the beneficial and harmful roles of complement in the pathogenesis of SLE, there are several hypothetic possibilities to modulate this system therapeutically (47,48). SLE is characterized by excessive IC formation and defective clearance by the mononuclear phagocyte system (49)(50)(51)(52). Handling of ICs by mononuclear phagocyte system (MPS) mostly depends on the function Fcγ receptors, which can be divided to two general classes: stimulatory and inhibitory.…”

Section: Anti-cytokine Therapy Soluble Mediatorsmentioning

confidence: 99%

Novel therapeutic approaches in systemic lupus erythematosus

Kiss

Szodoray²

2010

Front Biosci

View full text Add to dashboard Cite

Systemic lupus erythematosus is a prototypical systemic autoimmune disease, affecting multiple organs and organ-systems, leading to a wide variety of symptoms, serological and clinical features. The pathogenesis of the disease encompasses a complex interplay among various immune-competent cells and inflammatory mediators, which gives ground to target numerous potentially harmful players in this system. The aim of the present review was to depict certain aspects on the pathogenesis of SLE and to highlight pathways that can be promising targets of novel therapeutic approaches. T-cell, B-cell targeting, modification of co-stimulatory pathways, anti-cytokine therapy, soluble mediators, as well as autologous stem cell transplantation have been addressed. Finally, we described potential side effects of these biologics.

show abstract

Section: Anti-cytokine Therapy Soluble Mediatorsmentioning

confidence: 99%

Novel therapeutic approaches in systemic lupus erythematosus

Kiss

Szodoray²

2010

Front Biosci

View full text Add to dashboard Cite

show abstract

Novel therapeutic possibilities in systemic lupus erythematosus

et al. 2010

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disorder involving different organs and organ systems with consequent characteristic clinical and serologic symptoms. Despite of the improvement in lupus survival, approximately 10-20% of patients do not respond to traditional immune suppressive therapies. Relapses are more frequent; e.g. after cyclophosphamide therapy diffuse proliferative nephritis flares in 1/3 of patients. Different immune competent cells and inflammatory mediators participate in the pathogenesis of SLE involving both the adaptive and innate immunity. Several pathogenic elements and mechanisms may serve as therapeutic targets, consequently. Authors summarize novel therapeutic possibilities and their mechanisms regarding the pathogenesis of SLE. Immune modulation of B and T cells, co-stimulatory pathways, cytokine network, soluble mediators and autologous hemopoietic stem cell transplantation are discussed.

show abstract

Determination of ligand binding capacity of soluble FcγRII and FcγRIII in sera of patients with SLE

Cited by 2 publications

References 11 publications

Novel therapeutic approaches in systemic lupus erythematosus

Novel therapeutic approaches in systemic lupus erythematosus

Novel therapeutic possibilities in systemic lupus erythematosus

Contact Info

Product

Resources

About